ALK negative
|
NSCLC
|
ALK negative
|
NSCLC
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
ALK negative
|
Mantle Cell Lymphoma
|
ALK negative
|
Mantle Cell Lymphoma
|
brentuximab vedotin Sensitive: A2 - Guideline
|
brentuximab vedotin Sensitive: A2 - Guideline
|
ALK negative
|
T Cell Non-Hodgkin Lymphoma
|
ALK negative
|
T Cell Non-Hodgkin Lymphoma
|
brentuximab vedotin Sensitive: B - Late Trials
|
brentuximab vedotin Sensitive: B - Late Trials
|
ALK negative
|
NHL
|
ALK negative
|
NHL
|
brentuximab vedotin Sensitive: B - Late Trials
|
brentuximab vedotin Sensitive: B - Late Trials
|
ALK negative
|
NSCLC
|
ALK negative
|
NSCLC
|
pembrolizumab + atezolizumab Sensitive: B - Late Trials
|
pembrolizumab + atezolizumab Sensitive: B - Late Trials
|
ALK negative
|
NHL
|
ALK negative
|
NHL
|
etoposide IV Sensitive: C3 – Early Trials
|
etoposide IV Sensitive: C3 – Early Trials
|
ALK negative
|
NSCLC
|
ALK negative
|
NSCLC
|
sintilimab Sensitive: C3 – Early Trials
|
sintilimab Sensitive: C3 – Early Trials
|